Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?

GE HealthCare (GEHC) is scheduled to report Q2 2025 results on July 30, with consensus estimates projecting 2.8% revenue growth to $4.97 billion but a 9% decline in EPS to $0.91, a notable shift from its historical earnings beats. While Imaging and Pharmaceutical Diagnostics segments are expected to maintain strong performance, the company faces significant headwinds from tariffs, anticipated to impact Q2 by nearly $100 million and contribute to an $0.85 full-year adjusted EPS drag, particularly affecting Patient Care Solutions' margins. Investors will focus on management's tariff mitigation strategies and innovation updates, especially as the Zacks model does not currently predict an earnings beat.

Analysis

GE HealthCare faces a mixed outlook for its second-quarter 2025 earnings, with consensus estimates pointing to a 2.8% year-over-year revenue increase to $4.97 billion but a notable 9% decline in earnings per share to $0.91. This projected earnings contraction, which contrasts with the company's consistent track record of beating estimates, is primarily attributed to a significant tariff headwind expected to impact results by nearly $100 million in the quarter. The company's segment performance is highly divergent: the Pharmaceutical Diagnostics (PDx) and Imaging segments are expected to remain strong growth drivers, with PDx benefiting from 8% organic growth in the prior quarter and an acquisition set to add approximately $150 million in revenue for the remainder of the year. Conversely, the Patient Care Solutions (PCS) segment is a source of concern, having experienced a 450-basis point EBIT margin decline in Q1 due to tariffs and unfavorable product mix, with margin recovery expected to be protracted. While innovation, including the launch of the Flyrcado PET imaging tracer, provides a positive long-term catalyst, the immediate financial outlook is cautious, a sentiment reinforced by the Zacks model which does not conclusively predict an earnings beat.

Key Decisions for Investors

• Investors should pay close attention to management's commentary on tariff mitigation efforts, as the anticipated $100 million Q2 impact is the primary driver of the projected 9% EPS decline.
• Consider the divergent performance between segments, recognizing that the strength in the high-margin Pharmaceutical Diagnostics and Imaging divisions is being partly offset by significant margin pressure in the Patient Care Solutions business.
• Given the conflict between a history of earnings beats and a cautious quantitative model, it may be prudent to hold existing positions without adding exposure until the company provides clarity on the full-year impact of tariffs and margin recovery.
• For a long-term thesis, monitor the commercial traction of the new Flyrcado drug and any updates on the regulatory submission of the photon-counting CT system, as these innovations are crucial to offsetting near-term profitability challenges.